Ineffectiveness of ascorbic acid therapy in nephropathic cystinosis.
Because high concentrations of ascorbic acid (0.57 mM) lower the free (nonprotein) cystine content of cultured cystinotic skin fibroblasts by over 50 per cent, we did a double-blind clinical trial to establish whether this drug would benefit cystinotic children. Sixty-four patients were randomized into the study; 32 received ascorbic acid (200 mg per kilogram of body weight per day), and 32 placebo. The study was terminated after approximately two years because there was no indication that vitamin C was beneficial and accumulating evidence that it might be harmful. Of 11 patients who left the study because of death or the requirement for dialysis or renal transplantation, eight were receiving ascorbic acid. The estimated relative risk (treatment vs. control) of an adverse event was R = 2.7, with a 90 per cent confidence interval of (0.8, 11.5). The serum creatinine concentration increased 0.53 mg per deciliter per year in patients receiving vitamin C and 0.24 mg per deciliter per year in patients receiving placebo (P = 0.08).
D001205:Ascorbic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001806:Blood Urea Nitrogen; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D003553:Cystine / Q000097:blood; D003554:Cystinosis / Q000097:blood / Q000188:drug therapy*; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006400:Hematocrit; D006801:Humans; D007962:Leukocytes / Q000378:metabolism; D008297:Male; D012306:Risk
D003553:Cystine; D003404:Creatinine; D001205:Ascorbic Acid